Infliximab induced T lymphocyte apoptosis in Crohn's disease

Jan M.H. Van Den Brande*, Daan W. Hommes, Maikel P. Peppelenbosch

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

28 Citations (Scopus)


Crohn's disease (CD) is a chronic inflammatory disorder of the gastrointestinal tract of unknown origin. Therapies include immune modulating agents, biological therapies, and surgery. The activity and efficacy of the anti-tumor necrosis factor (TNF) therapies infliximab and etanercept have proved to be different: infliximab is effective to induce and maintain remission in refractory CD, while etanercept is not. This brief review considers the question of whether this disparity can be explained by the different structure of the proteins, their different binding affinities, or the subsequent effects on T lymphocytes.

Original languageEnglish
Pages (from-to)26-30
Number of pages5
JournalJournal of Rheumatology
Issue numberSUPPL. 74
Publication statusPublished - Mar 2005
Externally publishedYes


Dive into the research topics of 'Infliximab induced T lymphocyte apoptosis in Crohn's disease'. Together they form a unique fingerprint.

Cite this